Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older
出版年份 2023 全文链接
标题
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older
作者
关键词
-
出版物
Expert Review of Vaccines
Volume -, Issue -, Pages -
出版商
Informa UK Limited
发表日期
2023-10-25
DOI
10.1080/14760584.2023.2274491
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
- (2023) Xinxue Liu et al. JOURNAL OF INFECTION
- Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
- (2022) Jingxin Li et al. NATURE MEDICINE
- Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
- (2022) Yihao Liu et al. Cell Discovery
- Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults
- (2022) Lianpan Dai et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
- (2022) Pengfei Jin et al. PLOS MEDICINE
- Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
- (2022) Zhuxiang Zhao et al. Emerging Microbes & Infections
- Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
- (2022) Mayan Gilboa et al. JAMA Network Open
- Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
- (2022) Lairun Jin et al. Emerging Microbes & Infections
- Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)
- (2022) Yuting Liao et al. Frontiers in Immunology
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
- (2021) Shilong Yang et al. LANCET INFECTIOUS DISEASES
- Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
- (2021) Yunlong Cao et al. CELL RESEARCH
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
- (2021) Nawal Al Kaabi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
- (2021) Xinxue Liu et al. LANCET
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2021) Alberto M Borobia et al. LANCET
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- (2021) Ann R. Falsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- A practice of using five-colour chart to guide the control of COVID-19 and resumption of work in Zhejiang Province, China
- (2021) Fan He et al. Scientific Reports
- Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
- (2021) David Hillus et al. Lancet Respiratory Medicine
- Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern
- (2021) Jingwen Ai et al. CELL RESEARCH
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
- (2021) Alasdair P S Munro et al. LANCET
- Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
- (2021) Gang Zeng et al. LANCET INFECTIOUS DISEASES
- Boosting immunity to COVID-19 vaccines
- (2021) Jennifer A. Juno et al. NATURE MEDICINE
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
- (2021) Einav G. Levin et al. NEW ENGLAND JOURNAL OF MEDICINE
- From SARS to the Omicron variant of COVID-19: China's policy adjustments and changes to prevent and control infectious diseases
- (2021) Mingyu Luo et al. BioScience Trends
- A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
- (2020) Lianpan Dai et al. CELL
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- From Vaccines to Memory and Back
- (2010) Federica Sallusto et al. IMMUNITY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started